二甲双胍在前列腺癌治疗中的研究进展

Research progress in metformin for treatment of prostate cancer

摘要: 前列腺癌患者经过雄激素剥夺疗法(ADT)治疗, 前列腺癌细胞适应低雄激素环境后，病情将不可避免地进展为去势抵抗性前列腺癌(CRPC)。近年来研究发现单独或联合二甲双胍(MF)治疗有可能延缓中老年前列腺癌的发展。本文就MF对前列腺癌作用的研究进展予以简要综述。

Abstract: After treating by androgen deprivation therapy (ADT) in patients with prostate cancer, the prostate cancer cells gradually adapt to low androgen environments, and condition of disease will inevitably evolve to castration resistant prostate cancer (CRPC). In recent years, studies have found that single or combined treatment with metformin (MF) may delay the development of prostate cancer in the middle-aged and elderly patients. This paper aimed to take a brief review of the research progress on the effect of MF on prostate cancer.